Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
277.41
+4.50 (1.65%)
Jan 29, 2026, 11:17 AM EST - Market open
Krystal Biotech Stock Forecast
Stock Price Forecast
The 10 analysts that cover Krystal Biotech stock have a consensus rating of "Strong Buy" and an average price target of $250.5, which forecasts a -9.70% decrease in the stock price over the next year. The lowest target is $176 and the highest is $336.
Price Target: $250.5 (-9.70%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 6 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $288 → $318 | Strong Buy | Maintains | $288 → $318 | +14.63% | Jan 22, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $320 → $336 | Strong Buy | Maintains | $320 → $336 | +21.12% | Jan 12, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $202 → $306 | Strong Buy | Maintains | $202 → $306 | +10.31% | Jan 9, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $309 → $320 | Strong Buy | Maintains | $309 → $320 | +15.35% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $240 → $310 | Strong Buy | Reiterates | $240 → $310 | +11.75% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
395.50M
from 290.52M
Increased by 36.14%
Revenue Next Year
563.12M
from 395.50M
Increased by 42.38%
EPS This Year
6.41
from 3.00
Increased by 113.72%
EPS Next Year
8.10
from 6.41
Increased by 26.40%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 418.9M | 669.2M | ||||
| Avg | 395.5M | 563.1M | ||||
| Low | 373.9M | 426.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 44.2% | 69.2% | ||||
| Avg | 36.1% | 42.4% | ||||
| Low | 28.7% | 7.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7.42 | 10.28 | ||||
| Avg | 6.41 | 8.10 | ||||
| Low | 4.91 | 4.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 147.5% | 60.3% | ||||
| Avg | 113.7% | 26.4% | ||||
| Low | 63.7% | -31.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.